Vectura achieves £9m royalty cap

Vectura Group says it has achieved the £9m calendar year royalty cap on net sales of GSK’s Ellipta products in 2016.

This was a year earlier than previously guided, and was based on the continued strong performance of Ellipta products and the group’s subsequent receipt of its royalty statement from GSK.

Vectura receives a low single-digit percentage royalty on net sales of Ellipta products under a legacy Skyepharma agreement with GSK, subject to a cap of £9m per calendar year.

The group said it would record £5.4m of this capped amount in its 2016 revenues, representing income since 10 June 2016, the effective date of the merger with Skyepharma.

“This is additional to the royalties earned in respect of a separate Vectura legacy agreement with GSK which was subject to a £13m calendar year cap,” said Vectura.

As announced in July 2016, this cap was materially achieved before GSK decided not to extend the term of this latter agreement. Accordingly, for the financial year 1 April to 31 December 2016, the Group will record £7.3m royalties under this legacy agreement.

Story provided by

66% off newsstand price

12 issues (and much more) for just £12

That’s right. We’ll give you 12 issues of MoneyWeek magazine, complete access to our exclusive web articles, our latest wealth building reports and videos as well as our subscriber-only email… for just £12.

That’s just £1 per week for Britain’s best-selling financial magazine.

Click here to take advantage of our offer

Britain is leaving the European Union. Donald Trump is reducing America’s role in global markets. Both will have profound consequences for you as an investor.

MoneyWeek analyses the critical issues facing British investors on a weekly basis. And, unlike other publications, we provide you with the solutions to help you turn a situation to your financial advantage.

Take up our offer today, and we’ll send you three of our most important investment reports:

All three of these reports are yours when you take up our 12 issues for £12 offer today.

MoneyWeek has been advising private British investors on what to do with their money since 2000. Our calls over that period have enabled our readers to both make and save a great deal of money – hence our position as the UK’s most-trusted investment publication.

Click here to subscribe for just £12